ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1412

A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome

Ruth Napier1, Ellen Lee1, Emily Vance1, Sydney Lashley2, Luke Uebelhoer3, Christina Lancioni3, Richard Vehe4, Bryce Binstadt4, Rachel Caspi5 and Holly Rosenzweig1, 1Oregon Health & Science University and VA Portland Health Care System, Portland, OR, 2VA Portland Health Care System, Portland, OR, 3Oregon Health & Science University, Portland, 4University of Minnesota, Minneapolis, MN, 5NIH, Bethesda, MD

Meeting: ACR Convergence 2020

Keywords: autoimmune diseases, Autoinflammatory diseases, rheumatoid arthritis, T Cell, TH17 Cells

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2020

Title: T Cell Biology & Targets in Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Mutations in nucleotide-binding oligomerization domain-containing protein 2 (NOD2) cause Blau syndrome, an inflammatory disorder characterized by uveitis, dermatitis, and polyarthritis. The antimicrobial functions of NOD2 are well established; yet the mechanism by which dysregulated NOD2 causes sterile inflammation remain unknown. Here we utilized experimental models of autoimmune arthritis and uveitis, and PBMCs from Blau syndrome patients to dissect a T cell-specific role for NOD2 in uveitis.

Methods: Arthritis was induced in SKG and NOD2-/-SKG mice with a single intraperitoneal 1.5mg injection of zymosan and assessed by clinical scoring, near infrared imaging and histology. Uveitis was induced in NOD2+/+ and NOD2-/- C57BL/6 mice by immunization with the retinal antigen interphotoreceptor retinoid-binding protein (IRBP) and assessed by clinical scoring and histology. Mice were treated with IL-17A/F mAb (R&D systems) beginning 24h prior to disease induction. Lymphopenic Rag1-/- mice were reconstituted with NOD2-/- or NOD2+/+ (WT) CD4+ T cells and arthritis or uveitis was induced. IL-17 production by T cells was evaluated by flow cytometry and ELISA. For T cell homeostasis studies, purified naive (CD62LhiCD44–) CD4+ T cells were differentiated under Th17 polarizing conditions (CellXVivo) or purified memory (CD62L–CD44hi) CD4+ T cells from naive mice were stimulated with anti-CD3 and anti-CD28, and activation state (CD69) and pro-inflammatory cytokine production was determined by flow cytometry (n≥6 mice/group and repeated 3X). Peripheral blood mononuclear cells from Blau Syndrome patients or healthy controls were cultured for 5 d, stimulated with PMA/ionomycin, and IL-17 was measured. Data were analyzed by Mann-Whitney, and p< 0.05 were considered significant.

Results: Lymphopenic recipients of NOD2-deficient T cells developed significantly worse arthritis and uveitis, implicating T cell-intrinsic NOD2 in suppression of disease. CD4+ T cells purified from arthritic and uveitic mice produced significantly more IL-17, and blockade of IL-17 mitigated the enhanced disease caused by NOD2-deficiency, indicating a direct role for T cell-intrinsic NOD2 in suppressing autoreactive Th17 responses. NOD2 was dispensable for Th17 differentiation of naïve CD4+ T cells. However, NOD2-/- memory (antigen-experienced) CD4+ T cells isolated from naïve mice when stimulated with anti-CD3 and anti-CD28 had enhanced expression of IL-17, the IL-17-associated transcription factor (RORγt) and the activation marker CD69. Importantly, stimulation of CD4+ T cells from Blau syndrome patients resulted in significantly more IL-17 production than those from healthy control T cells, suggesting a similar function for NOD2 in human disease.

Conclusion: We have uncovered a novel, T cell-intrinsic function for NOD2 as a negative regulator of T cell homeostasis and autoimmunity. Our work suggests that a “loss-of-function” in NOD2 (i.e. NOD2-/- mice) results in a “gain-of-function” in the ability of T cells to produce IL-17 and cause arthritis and uveitis. These findings could potentially change the way we view the immunopathology of Blau syndrome and open up new therapeutic options for patients.


Disclosure: R. Napier, None; E. Lee, None; E. Vance, None; S. Lashley, None; L. Uebelhoer, None; C. Lancioni, None; R. Vehe, None; B. Binstadt, None; R. Caspi, None; H. Rosenzweig, None.

To cite this abstract in AMA style:

Napier R, Lee E, Vance E, Lashley S, Uebelhoer L, Lancioni C, Vehe R, Binstadt B, Caspi R, Rosenzweig H. A T Cell Intrinsic Role for Nod2 in Suppression of Th17-Mediated Experimental Arthritis and Uveitis: Implications for Blau Syndrome [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/a-t-cell-intrinsic-role-for-nod2-in-suppression-of-th17-mediated-experimental-arthritis-and-uveitis-implications-for-blau-syndrome/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-t-cell-intrinsic-role-for-nod2-in-suppression-of-th17-mediated-experimental-arthritis-and-uveitis-implications-for-blau-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology